

Shionogi Announces Corporate Reorganization and Personnel Reassignment

OSAKA, Japan, May 31, 2021 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that Shionogi will implement the following corporate reorganization and personnel reassignment as of July 1, 2021.

1. Corporate Reorganization (see attached organization chart)

(1) New establishment of the DX Promotion Division

The DX Promotion Division will be newly established to assume the role of creating healthcare solutions using digital technology, making use of data to support the realization of the solutions, and building IT and security infrastructure. The Digital Intelligence Department of the Corporate Strategy Division will be incorporated into the DX Promotion Division. In addition, the related functions of the Corporate Planning Department of the Corporate Strategy Division and the Data Science Office of the Integrated Disease Care Division will be reorganized into the IT & Digital Solution Department and the Data Science Department under the DX Promotion Division.

(2) Reorganization of the Pharmaceutical Research Division

The Biomarker R&D Department, which has been an independent organization, will be incorporated into the Pharmaceutical Research Division to further strengthen the collaboration between research on disease prevention and treatment and research on diagnosis and biomarkers.

(3) Reorganization of the Pharmaceutical Commercial Division

Under the reorganization of the functions of the Sales Planning Department, the Sales Planning Office, which is responsible for improving, reforming, and supervising the operations of the entire Pharmaceutical Commercial Division, and the Sales Promotion Office, which is responsible for planning and promoting sales activities, including promoting disease strategies through activities for core hospitals centered on university hospitals, will be newly established.

(4) Reorganization of the Integrated Disease Care Division

The Disease Care Strategy Department will be incorporated and integrated into the New Product Planning Department to make the commercial strategy globally consistent from the research phase to the post-marketing phase, thereby further enhancing the comprehensive strategy planning function related to healthcare services. The Disease Care Strategy Office will be established under the New Product Planning Department to take on the planning function for each disease area in Japan.

(5) Reorganization of the Global Business Division

The Global Supply Chain Strategy Department of the Corporate Strategy Division will be under the Global Business Division to strengthen the business collaboration between global business and procurement and supply strategy planning functions.

(6) Reorganization of the Corporate Strategy Division

The Business Development Department of the Global Business Division will be incorporated into the Corporate Strategy Division to more strategically promote collaborative creation with various partners, which is the core activity in our Medium-Term Business Plan “Shionogi Transformation Strategy 2030 (STS2030)”.

(7) Reorganization of the Administration Division

The Sustainability Management Office of the Corporate Planning Department, Corporate

Press Release



Strategy Division, will be incorporated as the Sustainability Management Department under the Administration Division to promote fair corporate activities and further enhance governance and compliance functions while deepening collaboration with organizations in each Division. Meanwhile, to make the independence of the internal audit function clearer, the Internal Control Department will be directly under the President, independent of all Divisions.

2. Personnel Reassignments (Effective; July 1, 2021)

New (or continuing) Position	Name	Present Position
DX Promotion Division		
Corporate Officer, Senior Vice President, DX Promotion Division and IT & Digital Solution Department	Takeshi Shiota	Corporate Officer, Senior Vice President, Corporate Planning Department
Vice President, Data Science Department	Yoshitake Kitanishi	Senior Director, Data Science Office
Pharmaceutical Research Division		
Senior Vice President, Pharmaceutical Research Division and Laboratory for Drug Discovery and Development	Jun Yoshimoto	Senior Vice President, Global Development Division and Clinical Research Department
Vice President, Research Planning Department	Shouko Kan-o	Project Management Department
Vice President, Laboratory for Drug Discovery and Disease Research	Gaku Sakaguchi	Vice President, Biomarker R&D Department
Vice President, Laboratory for Advanced Medicine Research	Takashi Mizukawa	Vice President, Research Planning Department
Vice President, Biomarker R&D Department	Tomoyuki Yukizawa	President, Shionogi Pharmacovigilance Center Co., Ltd.
Drug Development and Regulatory Science Division		
Vice President, Clinical Research Department	Takeki Uehara	Drug Development and Regulatory Science Division
Vice President, Pharmacovigilance Department	Masako Kaneto	Vice President, Laboratory for Drug Discovery and Development
CMC R&D Division		

Press Release



Senior Director, CMC Planning Office	Takeshi Sakai	CMC Planning Office
Vice President, API R&D Laboratory	Akira Ino	Vice President, Laboratory for Advanced Medicine Research
Vice President, Formulation R&D Laboratory	Minoru Hasegawa	Vice President, Laboratory for Drug Discovery and Disease Research
Vice President, Analytical R&D Laboratory	Yasunori Aoyama	Vice President, API R&D Laboratory
Pharmaceutical Commercial Division		
Senior Director, Sales Planning Office	Wataru Imamura	Sales Planning Department
Senior Director, Sales Promotion Office	Masanori Kuroiwa	Sales Planning Department
Senior Director, Specialty Product Office	Toshiyuki Aoi	Senior Director, Pharmaceutical Promotion Department - Region 5
Senior Director, Pharmaceutical Promotion Department - Region 2	Atsushi Nakamura	Sales Planning Department
Senior Director, Pharmaceutical Promotion Department - Region 4	Masashi Katsumata	President, Shionogi Marketing Solutions Co., Ltd.
Senior Director, Pharmaceutical Promotion Department - Region 5	Kazuya Ishida	Pharmaceutical Promotion Department - Region 6
Senior Director, Pharmaceutical Promotion Department - Region 6	Masao Morishita	Senior Director, Specialty Product Office
Senior Director, Pharmaceutical Promotion Department - Region 7	Souichirou Mitsutake	Sales Planning Department
Integrated Disease Care Division		
Senior Director, Disease Care Strategy Office	Yohji Urago	Disease Care Strategy Department
Vice President, Corporate Social Responsibility Department and Office for Children's Bright Future	Hiroyuki Tanaka	Vice President, Corporate Social Responsibility Department
Senior Director, Drug Information Center	Takashi Fukunaga	Medical Affairs Department
Corporate Quality Assurance Supervisor		
Vice President, Quality Assurance Department	Kumiko Numa	Vice President, Analytical R&D Laboratory

Press Release



Global Business Division		
Senior Executive Officer, Global Business Division	Kohji Hanasaki	Senior Executive Officer, Corporate Strategy Division
Corporate Strategy Division		
Senior Executive Officer, Corporate Strategy Division	John Keller	Senior Executive Officer, Global Business Division
Vice President, Corporate Planning Department	Susumu Mitsumori	Vice President, Disease Care Strategy Department
Administration Division		
Senior Executive Officer, Senior Vice President, Administration Division and Legal Affairs Department	Noriyuki Kishida	Senior Executive Officer, Senior Vice President, Administration Division
Vice President, Sustainability Management Department	Masako Kudou	Senior Director, Sustainability Management Office
Other		
Vice President, Internal Control Department	Kenji Matsuo	President, Shionogi Business Partner Co., Ltd.
Japanese group companies		
President, Shionogi Pharmacovigilance Center Co., Ltd.	Yuka Niimi	Pharmacovigilance Department
President, Shionogi Marketing Solutions Co., Ltd.	Minoru Mitsuda	Vice President, Commercial Division and Sales Planning Department
President, Shionogi Business Partner Co., Ltd.	Shigeki Fujita	Finance & Accounting Department

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological

Press Release



advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

SHIONOGI Website: <https://www.shionogi.com/global/en/contact.html>

SHIONOGI Divisions (July 1, 2021)

